On September 14, METIS TECHBIO-P fell 5.19% in regular trading, trading at 15.08 HKD/share, with turnover of approximately 6.53 million HKD.

On the news front, the stock has been under sustained selling pressure since September 10 as short-term profit-taking intensified. METIS TECHBIO-P was officially included in the Stock Connect program on September 7, which initially triggered a rally of over 40% within days as southbound capital flowed in. The rapid accumulation of short-term gains has led to persistent profit-taking over consecutive sessions.

The broader biotechnology sector remained weak, adding to downward pressure. Among sector peers, INNOVENT BIO fell 1.76%, QYUNS-B declined 1.48%, while AKESO edged up 0.28%. Additionally, the market is pricing in potential supply-side pressure from a cornerstone investor lock-up expiry window expected in mid-November, further weighing on sentiment.

METIS TECHBIO-P is a Beijing-based company focused on AI-driven nanomaterial innovation, with its core NanoForge platform powering solutions in drug delivery. The company reported first-half revenue of RMB 154 million, surging over 13,000% year-on-year.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)